Marcos Rogerio de Lima has been suspended after failing a drug test.
According to Combat Sports Anti-Doping (CSAD), the UFC’s drug-testing agency, de Lima tested positive for anastrozole, “a prohibited at all times substance” in the hormone and metabolic modulators class on the UFC’s prohibited substance list. The UFC heavyweight tested positive stemming from a Jan. 13 out-of-competition test.
This is the second time de Lima has tested positive for anastrozole, as he failed a test in 2017 where he served a reduced six-month suspension after USADA determined he used a contaminated supplement. This time, CSAD states that de Lima “submitted extensive medical documentation” in regards to a medical condition he suffered, and was prescribed something that had anastrozole listed on the label.
“De Lima neither checked on the prohibited status himself of the prescription before using it, nor contacted anyone within the UFC Anti-Doping Compliance Team for help to check the status of the prescription,” says the CSAD statement.
Additionally, CSAD says that after a thorough investigation, along with a detailed interview with de Lima — who was fully cooperative — along with contact with de Lima’s physician, CSAD confirmed the heavyweight fighter “was not seeking an athletic performance advantage and simply failed to check on the status of the medication and seek a therapeutic use exemption for his use of anastrozole.”
The anti-doping agency ultimately landed on a six-month suspension for de Lima, but since it was his second offense, the penalty was doubled to one year.
De Lima is eligible to compete again on Jan. 24, 2026
